Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses.
Pfeuffer S, Rolfes L, Wirth T, Steffen F, Pawlitzki M, Schulte-Mecklenbeck A, Gross CC, Brand M, Bittner S, Ruck T, Klotz L, Wiendl H, Meuth SG
Research article (journal) | Peer reviewedAbstract
In this observational study, patients with steroid-refractory acute multiple sclerosis relapses receiving either six courses of tryptophan-immunoadsorption or double-dose methylprednisolone therapy were analysed. Outcomes were evaluated at discharge and three months later. Immune profiling of blood lymphocytes and proteomic analysis were performed by multi-parameter flow cytometry and Olink analysis, respectively (NCT04450030).
Details about the publication
Journal: Journal of Neuroinflammation
Volume: 19
Issue: 1
Page range: 220-220
Status: Published
Release year: 2022 (07/09/2022)
Language in which the publication is written: English
Keywords: Humans; Methylprednisolone; Multiple Sclerosis; Prospective Studies; Proteomics; Quality of Life; Recurrence
Authors from the University of Münster
| Groß, Catharina | Department for Neurology |
| Klotz, Luisa Hildegard | Department for Neurology |
| Schulte-Mecklenbeck, Andreas | Department for Neurology |
| Wiendl, Heinz Siegfried | Department for Neurology |
| Wirth, Timo | University Children's Hospital Münster - Pediatric Rheumatology and Immunolgy |